One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Top 50 Most-Cited Journal of Clinical Oncology Articles From 2018
doi : 10.1200/JCO.21.00330
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1311-1313.
Precision Medicine in DLBCL: Are We There Yet?
Andrew J. Davies , PhD1
doi : 10.1200/JCO.20.03531
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1314-1316.
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S. Nowakowski , MD1; Annalisa Chiappella , MD2; Randy D. Gascoyne, MD3; David W. Scott , MBChB, PhD3; Qingyuan Zhang, MD4; Wojciech Jurczak, MD, PhD5; Muhit ?zcan , MD, PhD6; Xiaonan Hong, MD7; Jun Zhu, MD8; Jie Jin, MD9; David Belada, MD10; Juan Miguel Bergua , MD11; Francesco Piazza , MD12; Heidi M?cikova, MD13; Anna Lia Molinari, MD14; Dok Hyun Yoon, MD15; Federica Cavallo, MD16; Monica Tani, MD17; Kazuhito Yamamoto , MD, PhD18; Koji Izutsu, MD19; Koji Kato, MD20; Myron Czuczman, MD21; Sarah Hersey, MS, MBA, RAC22; Adrian Kilcoyne, MD21; Jacqueline Russo, BS21; Krista Hudak, PharmD21; Jingshan Zhang, PhD21; Steve Wade, BS23; Thomas E. Witzig , MD1; and Umberto Vitoloon behalf of the ROBUST Trial Investigators, MD2
doi : 10.1200/JCO.20.01366
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1317-1328.
Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL.
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S. Nowakowski , MD1; Fangxin Hong , PhD2; David W. Scott , MD3; William R. Macon, MD4; Rebecca L. King , MD4; Thomas M. Habermann, MD1; Nina Wagner-Johnston, MD5; Carla Casulo, MD6; James L. Wade , MD7; Gauri G. Nagargoje, MD8; C. M. Reynolds, MD9; Jonathon B. Cohen , MD, MS10; Nadia Khan , MD11; Jennifer E. Amengual , MD12; Kristy L. Richards, MD, PHD13,†; R. F. Little , MD14; John P. Leonard, MD13; Jonathan W. Friedberg, MD, MMSc6; Lale Kostakoglu , MD, MPH15; Brad S. Kahl , MD16; and Thomas E. Witzig , MD1
doi : 10.1200/JCO.20.01375
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1329-1338.
Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell–like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized phase II study comparing R2CHOP versus R-CHOP in untreated DLBCL.
Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials
Joseph M. Unger , PhD1,2; Anna B. Moseley , MS1,2; Christabel K. Cheung , PhD3; Raymond U. Osarogiagbon , MD4; Banu Symington, MD5; Scott D. Ramsey , MD, PhD2; and Dawn L. Hershman , MD6
doi : 10.1200/JCO.20.02602
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1339-1348.
Patients with cancer living in socioeconomically disadvantaged areas have worse cancer outcomes. The association between socioeconomic deprivation and outcomes among patients with cancer participating in clinical trials has not been systematically examined.
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Taofeek K. Owonikoko , MD, PhD1; Keunchil Park , MD, PhD2; Ramaswamy Govindan , MD3; Neal Ready, MD, PhD4; Martin Reck , MD, PhD5; Solange Peters , MD, PhD6; Shaker R. Dakhil, MD7; Alejandro Navarro, MD8; Jer?nimo Rodr?guez-Cid , MD9; Michael Schenker, MD, PhD10; Jong-Seok Lee, MD, PhD11; Vanesa Gutierrez, MD12; Ivor Percent, MD13; Daniel Morgensztern , MD3; Carlos H. Barrios , MD14; Laurent Greillier , MD, PhD15; Sofia Baka, MD, PhD16; Miten Patel, MD17; Wen Hong Lin, MD18; Giovanni Selvaggi, MD18; Christine Baudelet, PhD18; Jonathan Baden, MSc18; Dimple Pandya, MD18; Parul Doshi, PhD18; and Hye Ryun Kim , MD, PhD19
doi : 10.1200/JCO.20.02212
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1349-1359.
In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC.
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Aditya Bardia , MD, MPH1; Virginia Kaklamani , MD2; Sharon Wilks, MD3; Amy Weise, MD4; Donald Richards, MD5; Wael Harb, MD6; Cynthia Osborne, MD7; Robert Wesolowski , MD8; Meghan Karuturi, MD9; Paul Conkling, MD10; Rebecca G. Bagley, MS11; Yamei Wang , PhD11; Maureen G. Conlan, MD11; and Peter Kabos , MD12
doi : 10.1200/JCO.20.02272
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1360-1370.
This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer, including those with estrogen receptor gene alpha (ESR1) mutation. The primary objective was to determine the maximum tolerated dose and/or recommended phase II dose (RP2D).
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
Samuel R. Denmeade, MD1; Hao Wang, PhD1; Neeraj Agarwal, MD2; David C. Smith, MD3; Michael T. Schweizer, MD4; Mark N. Stein, MD5; Vasileios Assikis, MD6; Przemyslaw W. Twardowski, MD7; Thomas W. Flaig, MD8; Russell Z. Szmulewitz, MD9; Jeffrey M. Holzbeierlein, MD10; Ralph J. Hauke, MD11; Guru Sonpavde, MD12; Jorge A. Garcia, MD13; Arif Hussain, MD14; Oliver Sartor, MD15; Shifeng Mao, MD16; Harry Cao, BS1; Wei Fu, PhD1; Ting Wang, BS1; Rehab Abdallah, MD1; Su Jin Lim, ScM1; Vanessa Bolejack, PhD17; Channing J. Paller, MD1; Michael A. Carducci, MD1; Mark C. Markowski, MD1; Mario A. Eisenberger, MD1; and Emmanuel S. Antonarakis, MD1 on behalf of the TRANSFORMER Investigators
doi : 10.1200/JCO.20.02759
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1371-1382.
Prostate cancer (PCa) becomes resistant to androgen ablation through adaptive upregulation of the androgen receptor in response to the low-testosterone microenvironment. Bipolar androgen therapy (BAT), defined as rapid cycling between high and low serum testosterone, disrupts this adaptive regulation in castration-resistant PCa (CRPC).
Next-Generation Endocrine Therapies for Breast Cancer
Donald P. McDonnell, PhD1; Suzanne E. Wardell, PhD1; Ching-Yi Chang, PhD1; and John D. Norris, PhD1
doi : 10.1200/JCO.20.03565
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1383-1388.
Management of Dyspnea in Advanced Cancer: ASCO Guideline
David Hui , MD1; Kari Bohlke , ScD2; Ting Bao , MD3; Toby C. Campbell, MD, MS4; Patrick J. Coyne, MSN, ACHPN, ACNS-BC5; David C. Currow , BMed, MPH, PhD6; Arjun Gupta , MD7; Aliza L. Leiser, MD8; Masanori Mori , MD9; Stefano Nava, MD10; Lynn F. Reinke , PhD, ARNP11; Eric J. Roeland , MD12; Carole Seigel, MBA13; Declan Walsh , MD, MSc14; and Margaret L. Campbell , PhD, RN15
doi : 10.1200/JCO.20.03465
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1389-1411.
How Can We Distinguish Sorafenib-Associated Skin Rash From Skin Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation?
Shigeo Fuji, MD, PhD
doi : 10.1200/JCO.20.02228
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1412-1412.
Reply to S. Fuji
Andreas Burchert , MD, Stephan K. Metzelder, MD, Andreas Neubauer , MD, Michael Wittenberg, PhD, and Carmen Schade-Brittinger
doi : 10.1200/JCO.20.02891
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1412-1413.
Erratum
doi : 10.1200/JCO.21.00699
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1414-1414.
Erratum
doi : 10.1200/JCO.21.00677
Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1414-1414.
